

September 17, 2010

Ei Yamada, CEO

FOR IMMEDIATE RELEASE

AnGes MG, Inc.

(Code No.4563, TSE Mothers)

Contact: Fumihiko Suzuki, Manager, Business Planning Dept.

Tel: +81-3-5730-2480

Revised Full-Year Business Forecasts

AnGes MG, Inc. announced today that it has revised the business forecast for the fiscal year 2010 (January through December), published on February 5, 2010.

1. Revised consolidated financial forecast for FY 2010 (From Jan. 1, 2010 to December 31, 2010)

(million Yen)

	Revenues	Operating loss	Ordinary loss	Net loss	Net loss per share
Previous forecast (A)	500 ~ 800	(2,400)~(2,100)	(2,300)~(2,000)	(2,300)~(2,000)	-
Revised forecast (B)	300	(2,300)	(2,100)	(2,100)	-
Difference (B-A)	(500)	-	-	-	
Difference (%)	(40.0)	-	-	-	
Consolidated figures for FY 2009	585	(2,610)	(2,783)	(2,921)	-

2. Background of the revision

AnGes Group has been engaged in marketing of Naglazyme[®] (Enzyme replacement therapy for Mucopolysaccharidosis type IV) as well as research and development of genetic medicines, including Collategene[™], a HGF gene therapy.

In 2010, while sales of Naglazyme[®] met the sales forecast, AnGes made a decision to temporarily withdraw its pending Japanese BLA in favor of conducting an additional global clinical study, as announced separately. This will cause the milestone payment from AnGes' licensee to be postponed, therefore making it difficult to meet the originally projected revenue.

However, since all estimated expenses relating to the launch of Collategene[™] will not be incurred within this year, and as AnGes has successfully reduced its in-house R & D expenses, the ordinary loss is expected to be within the range of the original projection.

###